Entrada Therapeutics (NASDAQ:TRDA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Entrada Therapeutics (NASDAQ:TRDA) from a sell rating to a hold rating in a research note issued to investors on Monday morning,Wall Street Zen reports.

Several other equities analysts also recently weighed in on the stock. Weiss Ratings upgraded shares of Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, November 4th. Roth Capital restated a “buy” rating and set a $11.00 price target on shares of Entrada Therapeutics in a research note on Wednesday, August 12th. HC Wainwright restated a “neutral” rating on shares of Entrada Therapeutics in a research note on Monday, October 19th. Finally, UBS Group reaffirmed a “neutral” rating on shares of Entrada Therapeutics in a report on Monday, October 19th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $17.75.

Entrada Therapeutics Stock Up 3.6%

Shares of NASDAQ TRDA opened at $5.44 on Monday. Entrada Therapeutics has a one year low of $4.11 and a one year high of $16.45. The business’s fifty day moving average price is $5.68 and its 200-day moving average price is $8.48.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.94) earnings per share for the quarter, topping the consensus estimate of ($1.01) by $0.07. Entrada Therapeutics had a negative return on equity of 64.00% and a negative net margin of 4,057.98%. The company had revenue of $0.91 million during the quarter, compared to analyst estimates of $2.30 million. As a group, equities analysts anticipate that Entrada Therapeutics will post -4.16 EPS for the current fiscal year.

Insider Transactions at Entrada Therapeutics

In other Entrada Therapeutics news, major shareholder Bioventures 2014 L.P. Mpm sold 14,569 shares of Entrada Therapeutics stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $7.06, for a total transaction of $102,857.14. Following the completion of the transaction, the insider owned 4,318,348 shares of the company’s stock, valued at $30,487,536.88. The trade was a 0.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Bioventures 2018 L.P. Mpm sold 28,837 shares of the company’s stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $7.13, for a total value of $205,607.81. Following the sale, the insider owned 3,885,115 shares in the company, valued at approximately $27,700,869.95. This represents a 0.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 495,947 shares of company stock worth $3,600,470 in the last three months. 9.49% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Entrada Therapeutics

Large investors have recently modified their holdings of the company. Russell Investments Group Ltd. boosted its holdings in Entrada Therapeutics by 14.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 26,776 shares of the company’s stock valued at $170,000 after purchasing an additional 3,326 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in shares of Entrada Therapeutics by 24.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 116,596 shares of the company’s stock worth $740,000 after purchasing an additional 23,058 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Entrada Therapeutics by 118.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 60,704 shares of the company’s stock worth $380,000 after buying an additional 32,926 shares in the last quarter. Odyssean LLC purchased a new stake in shares of Entrada Therapeutics in the second quarter worth $230,000. Finally, Nantahala Capital Management LLC purchased a new stake in shares of Entrada Therapeutics in the second quarter worth $2,212,232. 86.39% of the stock is currently owned by institutional investors.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc. (NASDAQ:TRDA) is a biotechnology company focused on developing therapeutics designed to enter cells and address diseases caused by abnormal or missing intracellular proteins. The company’s approach is based on its Endosomal Escape Vehicle (EEV) platform, which is intended to deliver therapeutic payloads into target cells while helping them escape the endosome, a cellular compartment that can limit the effectiveness of some treatments. Entrada is developing EEV-based medicines for serious diseases, particularly genetic and neuromuscular conditions.